Daré Bioscience
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3655 Nobel Dr Ste 260, San Diego, Califo...Phone Number
(858) 926-7655Website
www.darebioscience.comRevenue
<$5 MillionStock Symbol
DAREIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Daré Bioscience
Daré Bioscience is a women’s health biotechnology company developing and commercializing innovative therapies for contraception, vaginal health, sexual health, fertility, menopause, and infectious disease. It advances science-backed products through clinical development, regulatory pathways, strategic partnerships, and commercialization to address unmet healthcare needs.Explore more
Daré Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Daré Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Daré Bioscience has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Daré Bioscience has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Daré Bioscience had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Daré Bioscience
Check out if Daré Bioscience is spiking on competitors!
Product Launch: Get notified when Daré Bioscience launches new products
Earning: See what the market has to say on Daré Bioscience recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Daré Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Daré Bioscience as Masked Content
Find 2 more new buyers
Compare Similar Companies to Daré Bioscience
Compare insights from companies similar to Daré Bioscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Daré Bioscience financials insights
Gather financial insights about Daré Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Multiple Rounds
$22.1M
2023
Other Financing Round
$12M
2024
Grant
$2.5M
2026
Unspecified
$908K
Daré Bioscience Tech Stack
A closer look at the technologies used by Daré Bioscience
Most Recent Scoops
Project
Daré Bioscience is conducting a pivotal Phase III clinical trial for Ovaprene, a first-in-category non-hormonal, once-a-month vaginal contraceptive, with two positive interim data safety monitoring board meetings completed and enrollment expected to be finalized later this year. Top-line data from the trial is anticipated in 2027, with the product having the potential to become the first FDA-approved monthly hormone-free contraceptive.
Product Development, Pharmaceuticals, Clinical Operations
Project
Daré Bioscience is planning to initiate an NIH-funded Phase I clinical study for a progesterone vaginal ring designed as an alternative to progesterone injections for IVF and for maintaining pregnancy during at-risk pregnancies.
Medical Research, Pharmaceuticals, Clinical Operations
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Daré Bioscience News & Media
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 millionDaré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Video webcast now available hereDaré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necessary to advance its Sildenafil Cream toward the FDA’s 505(b)(2) regulatory pathway* while in parallel launching DARE to PLAY™ Sildenafil Cream, the 503B compounded version of its proprietary sildenafil cream formulation**Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
President & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 months Access the segment here
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Daré Bioscience
Sign Up For FreeTo access detailed company insights
Daré Bioscience is a women’s health biotechnology company developing and commercializing innovative therapies for contraception, vaginal health, sexual health, fertility, menopause, and infectious disease. It advances science-backed products through clinical development, regulatory pathways, strategic partnerships, and commercialization to address... Read More
